Nebenwirkungen · Conexxence
Conexxence 60 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7–8
HOS-152345 · Präparat HOS-100733
Skin infections In phase III placebo-controlled clinical trials, the overall incidence of skin infections was similar in the placebo and the denosumab groups: in postmenopausal women with osteoporosis (placebo [1.2%, 50 out of 4,041] versus denosumab [1.5%, 59 out of 4,050]); in men with osteoporosis (placebo [0.8%, 1 out of 120] versus denosumab [0%, 0 out of 120]); in breast or prostate cancer patients receiving hormone ablation (placebo [1.7%, 14 out of 845] versus denosumab [1.4%, 12 out of 860]). Skin infections leading to hospitalisation were reported in 0.1% (3 out of 4,041) of postmenopausal women with osteoporosis receiving placebo versus 0.4% (16 out of 4,050) of women receiving denosumab. These cases were predominantly cellulitis. Skin infections reported as serious adverse reactions were similar in the placebo (0.6%, 5 out of 845) and the denosumab (0.6%, 5 out of 860) groups in the breast and prostate cancer studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T23:00:00Z · SHA-256 3b88e805c7567f6fffd8772623b663b6b876e38ae5fddfae90c285733d588e23 · Passage a4c7fe45a0ff4e880ee0643f82a45e4f9d7bdf2b4bbb8354e110b2718d81a59a · Zeichen 4972–5916 im Abschnitt